Literature DB >> 15343248

Diagnostic mid trimester amniocentesis: how safe?

John W Seeds1.   

Abstract

OBJECTIVE: Genetic mid-trimester amniocentesis is a common invasive procedure. The origin of the commonly quoted 0.5% rate of procedure-related pregnancy loss after amniocentesis is obscure and is in conflict with the only randomized prospective study that reported a procedure-related rate of loss of 1.0%. This review was performed to establish an estimate of procedure-related pregnancy loss after mid-trimester amniocentesis. The impact of placental puncture on the rate of loss and the risk of direct needle injury to the fetus were also examined. STUDY
DESIGN: The National Library of Medicine database was used to identify English language reports of >1000 amniocenteses with sufficient detail and follow up data to allow the calculation of the rate of spontaneous pregnancy loss after amniocentesis but before 28 completed weeks. These reports were divided into 2 groups to assess the impact of the ultrasound technique. Group I described only preamniocentesis ultrasound evaluation; group II described primarily concurrent ultrasound needle guidance. Pregnancy loss between the 2 groups was compared. The impact of placental puncture and reported direct fetal trauma were examined. The significance of differences was tested using chi-square analysis, with significance at a probability value of < or =.05.
RESULTS: Twenty-nine reports that totaled 68,119 amniocenteses were examined. In a comparison of all studies in group I with all studies in group II, there was a lower rate of loss after amniocenteses with the use of concurrent guidance (1.4%) compared with the use of preamniocentesis ultrasound evaluation (2.1%) that was significant ( P <.001). Among only the 5 controlled studies that used preamniocentesis ultrasound evaluation, the difference in rate of loss between amniocentesis patients and control subjects was 0.6% ( P =.0042; 95% CI, 0.19, 1.03), which was identical to the difference in the rate of loss of 0.6% between amniocentesis patients and control subjects from the 5 controlled studies that used concurrent ultrasound needle guidance ( P <.0001; 95% CI, 0.31, 0.90). Multiple case reports and small series of presumed fetal needle trauma were reviewed, but most of these attributed causation to the amniocentesis needle based only on circumstantial association. Two cases with direct evidence of fetal needle trauma are discussed. Finally, the rate of loss after placental puncture from among 9 reports that provided this detail was 1.4% and not different from the overall rate of loss that was noted in group II.
CONCLUSION: This examination of experience with 68,119 amniocenteses from both controlled and uncontrolled studies provides a substantive basis for several conclusions: (1) Contemporary amniocentesis with concurrent ultrasound guidance in controlled studies appears to be associated with a procedure-related rate of excess pregnancy loss of 0.6% (95% CI, 0.31, 0.90). To determine the total rate of loss, this must be added to the reported natural rate of loss without amniocentesis among control patients of 1.08%. (2) The use of concurrent ultrasound guidance appears to reduce the number of punctures and the incidence of bloody fluid. Concurrent ultrasound guidance was associated with a reduced rate of loss when all studies were compared, but not among controlled studies. (3) Direct fetal needle trauma is rare, and rarely proved, but may occur more frequently than is reported because of a failure to diagnose and a failure of the consistent production of sequelae. (4) This experience does not substantiate an increased rate of pregnancy loss if placental puncture is required.

Entities:  

Mesh:

Year:  2004        PMID: 15343248     DOI: 10.1016/j.ajog.2004.05.078

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  10 in total

1.  Testing for maternal cell contamination in prenatal samples: a comprehensive survey of current diagnostic practices in 35 molecular diagnostic laboratories.

Authors:  Iris Schrijver; Sarah C Cherny; James L Zehnder
Journal:  J Mol Diagn       Date:  2007-07       Impact factor: 5.568

2.  Prenatal testing for Down syndrome: comparison of screening practices in the UK and USA.

Authors:  Dagmar Tapon
Journal:  J Genet Couns       Date:  2009-11-03       Impact factor: 2.537

3.  Comparison of indications and results of prenatal invasive diagnostic tests before and after the implementation of the use of cell-free fetal DNA: a tertiary referral center experience.

Authors:  Firat Okmen; Huseyin Ekici; Ismet Hortu; Metehan Imamoglu; Duygu Arican; Haluk Akın; Sermet Sagol
Journal:  J Assist Reprod Genet       Date:  2020-05-21       Impact factor: 3.412

4.  Regulatory and ethical issues for phase I in utero gene transfer studies.

Authors:  Carson Strong
Journal:  Hum Gene Ther       Date:  2011-09-23       Impact factor: 5.695

Review 5.  Antithyroid drug-induced fetal goitrous hypothyroidism.

Authors:  Sofie Bliddal; Ase Krogh Rasmussen; Karin Sundberg; Vibeke Brocks; Ulla Feldt-Rasmussen
Journal:  Nat Rev Endocrinol       Date:  2011-03-15       Impact factor: 43.330

Review 6.  Calculation of Fetal Fraction for Non-Invasive Prenatal Testing.

Authors:  Matthew Cserhati
Journal:  BioTech (Basel)       Date:  2021-08-09

7.  Combined use of cytogenetic and molecular methods in prenatal diagnostics of chromosomal abnormalities.

Authors:  Meliha Stomornjak-Vukadin; Ilvana Kurtovic-Basic; Lejla Mehinovic; Rijad Konjhodzic
Journal:  Acta Inform Med       Date:  2015-04-14

8.  Prenatal Diagnosis Nomograms: A Novel Tool to Predict Fetal Chromosomal Abnormalities in High-Risk Patients.

Authors:  Yangzi Zhou; Zixuan Song; Lu Sun; Yuting Wang; Xiting Lin; Dandan Zhang
Journal:  Risk Manag Healthc Policy       Date:  2021-11-04

9.  Informatics-based, highly accurate, noninvasive prenatal paternity testing.

Authors:  Allison Ryan; Johan Baner; Zachary Demko; Matthew Hill; Styrmir Sigurjonsson; Michael L Baird; Matthew Rabinowitz
Journal:  Genet Med       Date:  2012-12-20       Impact factor: 8.822

10.  Noninvasive prenatal paternity testing by means of SNP-based targeted sequencing.

Authors:  Jacqueline Chor Wing Tam; Yee Man Chan; Shui Ying Tsang; Chung In Yau; Shuk Ying Yeung; Ka Ki Au; Chun Kin Chow
Journal:  Prenat Diagn       Date:  2020-02-20       Impact factor: 3.050

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.